Although the ex vivo DC loading approach is continuing to develop, with the latest advances as an application of HSP-TAAs complexes derived from DC/tumor FCs, or MHCs-epitopes bearing extracellular vesicles derived from ex vivo loaded DCs [257,258], in our subjective opinion, it makes sense to expect a greater development of the in vivo DC-targeting approach. The gene discussed is HSP90B2P; the disease is neoplasm.